Top in allergy/asthma: Dupilumab ineffective for peanut desensitization; asthma blood test
Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving dupilumab for 24 weeks.
They found that the use of adrenaline as rescue medication and grade 2 allergic reactions occurred more frequently during the challenge.
“The impact of the findings for the everyday clinician is that dupilumab monotherapy may not be an effective treatment for desensitization in patients with peanut allergy,” Sayantani B. Sindher, MD, clinical associate professor of medicine and pediatrics – allergy and clinical immunology at Sean N. Parker Center for Allergy and Asthma Research at Stanford University, told Healio. “However, the reduction in total IgE and [peanut-specific]-IgE levels, as well as the decrease in allergic reactions of grade 2 or higher, suggest that dupilumab may still have a role in managing symptoms and reducing the severity of allergic reactions.”
It was the top story in allergy/asthma last week.
Another top story included a blood test that used cyclic adenosine monophosphate to diagnose asthma and determine its severity.
Read these and more top stories in allergy/asthma below:
Dupilumab does not desensitize children with peanut allergy
Following receipt of dupilumab for 24 weeks, most children or adolescents with peanut allergy did not achieve desensitization to peanut exposure, according to study results published in Allergy. Read more.
Blood test uses cyclic adenosine monophosphate to diagnose asthma
Blood tests for cyclic adenosine monophosphate may be a simple and useful option for diagnosing asthma and determining its severity, according to a study published in The Journal of Clinical Investigation. Read more.
Maternal allergy status, infant birth season impact milk microbiome of mothers
Researchers identified a strong correlation between the milk microbiome of mothers with allergic disease and the season of infant birth, study results published in Allergy showed. Read more.
Disparities persist in testing for inborn errors of immunity despite sponsored program
Significant racial disparities persisted in genetic testing for inborn errors of immunity despite the removal of financial barriers, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Six-month asthma control score on mepolizumab predicts remission in eosinophilic asthma
Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was deemed “best predictor” of 12-month remission in patients with severe eosinophilic asthma, study results suggested. Read more.